Study on the role of the antioxidant enzyme peroxiredoxin in canine tumors.

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K06429
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 42020:Veterinary medical science-related
• Research Institution: Gifu University
• Principal Investigator: Sakai Hiroki 岐阜大学, 応用生物科学部, 教授 (40283288)
• Co-Investigator(Kenkyū-buntansha): 村上 麻美 岐阜大学, 応用生物科学部, 助教 (30597125)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: ペルオキシレドキシン / 犬 / 腫瘍

Outline of Final Research Achievements

The expression of PRDX1 and 2 in normal tissues of dogs was similar to that in other animal species. In canine squamous cell carcinoma, the positive score of PRDX1 was higher in oral squamous cell carcinoma with poor prognosis than in cutaneous squamous cell carcinoma, suggesting that PRDX1 may be involved in the malignant dynamics in oral squamous cell carcinoma. PRDX1 immunostaining may differentiate lymph node hyperplasia from lymphoma, as PRDX1 is negative in normal lymph nodes but positive in T-cell lymphomas. The positive scores of PRDX1 and PRDX2 were significantly higher in malignant hemangiosarcomas, and the suppression of PRDX1 expression in canine hemangiosarcoma cell lines suggests that PRDX1 may be involved in the increased cell proliferation of canine hemangiosarcoma cells.

Free Research Field

獣医病理学

Academic Significance and Societal Importance of the Research Achievements

本研究において，これまで報告のなかった犬の正常組織および腫瘍におけるPRDX1および2の発現についての免疫組織学的特徴を明らかにした。さらに扁平上皮癌，T細胞性リンパ腫，血管肉腫をはじめとした，いくつかの腫瘍では，腫瘍におけるPRDXの発現亢進の，腫瘍化や悪性化への関与が示唆された。